Related Experiment Videos
Immune thrombocytopenia and alpha-interferon therapy
S P Dourakis1, M Deutsch, S J Hadziyannis
1Academic Department of Medicine, Hippokration General Hospital, Athens, Greece.
Journal of Hepatology
|December 1, 1996
Summary
Severe immune thrombocytopenia is rare but can be induced by alpha-interferon therapy in patients with chronic hepatitis C. This condition, characterized by low platelet counts, can be successfully treated by discontinuing the drug and using steroids and immunoglobulins.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Background:
- Thrombocytopenia is common in liver disease, often linked to portal hypertension and splenomegaly.
- Immune thrombocytopenia (ITP) is rarely associated with hepatitis C virus (HCV) infection, potentially due to HCV's role in inducing autoimmunity.
- Interferons, used for HCV treatment, possess immunomodulatory effects that can trigger or worsen autoimmune conditions.
Observation:
- Mild thrombocytopenia is a known side effect of interferon therapy.
- Severe, life-threatening thrombocytopenia is an extremely rare adverse event.
- This report details two cases of severe ITP in chronic hepatitis C patients, suspected to be induced by alpha-interferon.
Findings:
- Bone marrow aspirates and elevated platelet-associated IgG antibodies supported an ITP diagnosis.
- Patients lacked clinical signs of other autoimmune syndromes, and cryoglobulins/rheumatoid factor were negative.
- The presentation strongly suggested drug-induced ITP, given alpha-interferon exposure and exclusion of other causes.
Implications:
- Alpha-interferon withdrawal, followed by prednisolone and immunoglobulin treatment, successfully resolved thrombocytopenia in both cases.
- The positive response to treatment reinforces the diagnosis of alpha-interferon-induced ITP.
- This highlights the critical need to monitor for severe ITP in patients receiving interferon therapy for chronic hepatitis C.